Gene therapy holds promise for chronic lymphocytic leukemia

08/10/2011 | Wall Street Journal, The · Reuters

Scientists at the University of Pennsylvania destroyed tumors in three patients with chronic lymphocytic leukemia less than a month after administering the patients' T-cells that were genetically engineered to stimulate the immune system to hone in on the CD19 protein, which is found on blood cancer cells. Two patients achieved complete response to the treatment, while the third exhibited partial response. The therapy needs to be tested in more patients to validate the findings, the study's principal investigator said.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX